Real world comparative outcomes of adjuvant carboplatin versus cisplatin-based chemotherapy in stage IB–IIIA non-small cell lung cancer: a propensity-weighted analysis
Molly Tokaz, Brendan T. Heiden, Daniel B. Eaton, Shadia Jalal, Nahom Seyoum, Whitney S. Brandt, Nikki E. Rossetti, Su-Hsin Chang, Yan Yan, Varun Puri, Martin W. Schoen, Theodore S. Thomas · 2026
Read Real world comparative outcomes of adjuvant carboplatin versus cisplatin-based chemotherapy in stage IB–IIIA non-small cell lung cancer: a propensity-weighted analysis by Molly Tokaz, Brendan T. Heiden, Daniel B. Eaton, Shadia Jalal, Nahom Seyoum, Whitney S. Brandt, Nikki E. Rossetti, Su-Hsin Chang, Yan Yan, Varun Puri, Martin W. Schoen, Theodore S. Thomas (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13358826.txt.
Description
Molly Tokaz and co-authors compare two platinum drugs after lung cancer surgery in a 2026 study. For early-stage non-small cell lung cancer removed by surgery, added chemotherapy lowers the risk of return. Cisplatin is the classic choice but is harsh on kidneys and ears. Carboplatin is gentler and often swapped in, though its real-world results were unclear.
Using national data on veterans treated from 2006 to 2020, the team balanced the two groups on key traits and compared survival, cancer return, kidney harm, and hospital stays. Such real-world proof matters because trial patients are often fitter than the people doctors treat every day.
Catalog record
| CREATOR | Molly Tokaz, Brendan T. Heiden, Daniel B. Eaton, Shadia Jalal, Nahom Seyoum, Whitney S. Brandt, Nikki E. Rossetti, Su-Hsin Chang, Yan Yan, Varun Puri, Martin W. Schoen, Theodore S. Thomas |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 42518 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |